Haemonetics (HAE) Tops Q4 EPS by 2c

Haemonetics (NYSE: HAE) reported Q4 EPS of $1.29, $0.02 better than the analyst estimate of $1.27. Revenue for the quarter came in at $346 million versus the consensus estimate of $337.04 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• ICICI Securities Downgrades Manappuram Finance Ltd (MGFL:IN) to Hold (3)